Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial-Reference-Cited by-同舟云学术

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial

Published:2015-07 Issue:7 Volume:16 Page:787-794
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Fizazi Karim,Faivre Laura,Lesaunier François,Delva Remy,Gravis Gwenaëlle,Rolland Frédéric,Priou Frank,Ferrero Jean-Marc,Houede Nadine,Mourey Loïc,Theodore Christine,Krakowski Ivan,Berdah Jean-François,Baciuchka Marjorie,Laguerre Brigitte,Fléchon Aude,Ravaud Alain,Cojean-Zelek Isabelle,Oudard Stéphane,Labourey Jean-Luc,Chinet-Charrot Paule,Legouffe Eric,Lagrange Jean-Léon,Linassier Claude,Deplanque Gaël,Beuzeboc Philippe,Davin Jean-Louis,Martin Anne-Laure,Habibian Muriel,Laplanche Agnès,Culine Stéphane

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Prostate cancer: ESMO Consensus Conference Guidelines 2012;Horwich;Ann Oncol,2013

2. National Comprehensive Cancer Network. Prostate cancer, version 2.2014;Mohler;J Natl Compr Canc Netw,2014

3. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy;Stephenson;J Clin Oncol,2005

4. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study;Bolla;Lancet Oncol,2010

5. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma— long-term results of phase III RTOG 85-31;Pilepich;Int J Radiat Oncol Biol Phys,2005

Cited by 204 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives;Clinical Genitourinary Cancer;2024-10

2. The Benefit of Combining Docetaxel with Androgen Deprivation Therapy in Localized and Metastatic Hormone-sensitive Prostate Cancer is Predicted by ERG Expression: An Analysis of Two GETUG Phase 3 Trials;European Urology Oncology;2024-07

3. Radiation Therapy for Locally Advanced Prostate Cancer: How Do We Treat Patients with cN1 Disease?;European Urology Focus;2024-07

4. La radiothérapie du cancer de la prostate augmente-t-elle le risque de seconds cancers ?;Cancer/Radiothérapie;2024-06

5. The intricate interplay between cancer stem cells and cell-of-origin of cancer: implications for therapeutic strategies;Frontiers in Oncology;2024-05-10